rethinkPeptides Search
Menu
Study breakdown

D-Amino Acids in Disease: When Mirror-Image Molecules Signal Something Wrong

ReviewN/A evidence
The takeaway

D-amino acids and D-amino acid-containing peptides accumulate in diseases like Alzheimer's and cataracts, potentially serving as both biomarkers for diagnosis and targets for new therapies.

Mirror-image amino acids found in multiple diseases

D-amino acid-containing peptides have been isolated from patients with cataracts, Alzheimer's disease, and other conditions where long-lived proteins undergo age-related modifications

What the researchers found

D-amino acids and D-amino acid-containing peptides (DAACPs) have been found in patients with cataracts, Alzheimer's disease, and other conditions, where they may serve as disease biomarkers or therapeutic targets. The spontaneous conversion of L-amino acids to their D-form in long-lived proteins alters protein structure and function, potentially contributing to disease progression. Elevated free D-amino acid levels in certain diseases reflect altered metabolism and may provide diagnostic value. Advances in analytical techniques are improving our ability to detect and study these mirror-image molecules.

Why it matters

Most biology assumes all amino acids are L-form, but D-amino acids accumulate naturally in aging tissues and diseased proteins. This review highlights an underappreciated dimension of peptide biochemistry: the spontaneous flip from L to D in proteins like beta-amyloid (Alzheimer's) and lens crystallins (cataracts) may actively drive disease rather than being a passive consequence. Understanding this process could reveal new diagnostic biomarkers and drug targets.

The numbers in context

DAACPs found in: cataracts, Alzheimer's disease, and other conditions · Free D-amino acids: altered levels in multiple diseases · Focus: L→D conversion in long-lived proteins

How the study worked

Literature review summarizing the occurrence of D-amino acids and DAACPs in disease, their molecular mechanisms of formation, links to disease development, and recent advances in analytical detection techniques.

Who was studied

Not applicable (review of D-amino acids in human disease)

What this study cannot tell us

Narrative review without systematic methodology. The field of D-amino acid biology in disease is still developing, with many findings correlational rather than causal. Analytical challenges in detecting D-amino acids have historically limited research in this area.

How to read the evidence

This is a narrative review summarizing an emerging field. The individual studies cited range from analytical chemistry to clinical observations. The evidence for D-amino acids as biomarkers is growing but not yet clinically validated. Evidence grading doesn't directly apply to methods reviews.

When this study was published

Published in 2021, this review captures a growing field enabled by improvements in chiral analytical techniques. Research on D-amino acids in disease continues to expand as detection methods improve.

The bigger picture

The presence of D-amino acids in disease adds a layer of complexity to peptide and protein biology that's often overlooked. In Alzheimer's disease, the discovery of D-aspartate and D-serine residues in amyloid-beta peptides suggests that age-related amino acid racemization could make these peptides more toxic or resistant to clearance. This intersects with the broader goal of understanding why protein aggregation diseases increase with age — the gradual accumulation of D-amino acid modifications may be one answer.

Questions still open

  • Could measuring D-amino acid levels in blood or cerebrospinal fluid provide early diagnostic biomarkers for Alzheimer's disease?
  • Do D-amino acid-containing amyloid-beta peptides resist degradation differently than their all-L counterparts, contributing to plaque persistence?
  • Can enzymes or drugs that specifically target D-amino acid-modified proteins be developed as therapies?

Common questions

What's the difference between L and D amino acids?
L and D amino acids are mirror images of each other, like left and right hands. Life almost exclusively uses L-amino acids to build proteins. D-amino acids are the same chemical formula but flipped in 3D space. When an L-amino acid spontaneously converts to D in a protein, it can change the protein's shape and function, potentially contributing to disease.
How do D-amino acids end up in diseased tissues?
In long-lived proteins that don't get replaced often (like eye lens proteins or brain amyloid deposits), L-amino acids can spontaneously convert to D-form over years or decades through a process called racemization. This is essentially a molecular aging process. The accumulation of these flipped amino acids may contribute to protein malfunction and disease.

Read the original research

D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?

Biomolecules, 11(11)

Citation

Abdulbagi, Mohamed; Wang, Liya; Siddig, Orwa; Di, Bin; Li, Bo. (2021). D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?. Biomolecules, 11(11). https://doi.org/10.3390/biom11111716